Immunological Phenotype of Desmoid-fibromatosis-affected Patients.

Recruiting now

Conditions studied: Desmoid-Type Fibromatosis

In brief

This observational study aims to characterize the molecular, phenotypic, and functional inflammatory and immunological profile of patients with sporadic desmoid-type fibromatosis undergoing either active surveillance or systemic therapy. The study includes analysis of the tumor immune microenvironment (TIME), circulating immune and inflammatory molecules, immune cell subsets, and circulating tumor DNA (ctDNA). The goal is to identify biomarkers associated with spontaneous or treatment-induced tumor regression and to evaluate potential correlations with specific ß-catenin mutations.

Key facts

Study ID

NCT07496242

Run by

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

People needed

200

Starts

2025-05-27

Expected to finish

2026-12-01

Last updated by the study team

2026-03-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with primary sporadic desmoid-type fibromatosis with measurable disease under active surveillance
• Patients with primary sporadic desmoid-type fibromatosis with measurable disease receiving systemic treatment.

Where it is running

• Fondazione IRCCS Istituto Nazionale dei Tumori — Milan, Italy (enrolling)
• Azienda Ospedaliero Universitaria Careggi — Florence, Italy
• Azienda Usl Toscana centro — Florence, Italy
• IRCCS Istituto Oncologico Veneto IOV — Padova, Italy
• Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" — Palermo, Italy
• Università Campus Bio-Medico — Rome, Italy
• IRCCS Istituto di Candiolo Fondazione del Piemonte per l'Oncologia — Candiolo, Italy
• Erasmus University Medical Centre — Rotterdam, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.